Congress Delays Action on Hemp THC Amendments Amid Intensifying Cannabis Reform Debate

Efforts to reshape federal regulations on hemp-derived THC products have hit a temporary standstill in Congress, as competing amendments failed to advance to a House floor vote this week. According to Marijuana Moment, one amendment seeking to delay the scheduled federal recriminalization of certain hemp THC products was withdrawn, while a rival proposal to accelerate the process was blocked by the House Rules Committee. The result is continued regulatory uncertainty for the hemp industry as stakeholders await Congress’s next move

This congressional pause comes at a time when cannabis policy is experiencing rapid evolution across the United States. In Maryland, Governor Wes Moore has signed a bill protecting the workplace rights of firefighters and rescue workers who use medical cannabis off duty. Meanwhile, North Carolina’s Senate President Pro Tempore Phil Berger signaled that his caucus will soon discuss possible medical cannabis legalization, citing momentum from the ongoing federal marijuana rescheduling process. These state-level actions reflect a broader national push to reconsider cannabis laws as federal policy shifts

The debate over hemp-derived THC products has become increasingly contentious, with lawmakers divided over public safety, industry innovation, and consumer access. During a recent visit to Pharm CBD in Kentucky, Sen. Rand Paul stated, “We discussed next steps, like my bipartisan Hemp Safety Enforcement Act,” highlighting bipartisan interest in establishing clear safety standards. Rep. Thomas Massie, who joined Paul at the event, added, “We heard first-hand testimony from families & veterans who have benefitted medically from hemp-derived products.” Their comments underscore the growing recognition of hemp’s therapeutic potential and the need for regulatory clarity

Amid federal gridlock, states and localities continue to chart their own course. Minnesota legislators are advancing a psilocybin bill, while an Oklahoma judge recently lifted a suspension on a medical cannabis business. Regulatory agencies in Colorado and New York have stepped up efforts to address scams and unlicensed operators, and New Jersey is working to help consumers identify legal dispensaries. These developments illustrate the patchwork nature of cannabis and hemp regulation in the U.S., with policies varying widely between states and often diverging from federal guidelines

As scientific research on cannabis expands, new findings are shaping the conversation. A recent archaeological study cited by Marijuana Moment revealed that by the Late Neolithic era, cannabis was a core crop in northern China, deeply integrated into daily life. Modern clinical reports also highlight cannabis oil’s potential for treating drug-resistant migraines, and reviews suggest promising outcomes for DMT-assisted psychotherapy in substance misuse treatment. These discoveries contribute to growing public and policymaker interest in cannabis as both an agricultural commodity and a therapeutic resource

From the OG Lab newsroom perspective, Congress’s decision to delay action on hemp THC amendments prolongs uncertainty for producers, consumers, and state regulators alike. This ongoing federal indecision comes as states continue to innovate and adapt, often outpacing national policy. As the cannabis industry awaits further movement in Congress, stakeholders should watch closely for new legislative proposals and evolving regulatory approaches that could reshape the future of hemp and cannabis in the U.S